Trial Profile
Randomized, Double-Blind, Placebo-Controlled Study of Nitazoxanide in the Treatment of Chronic Hepatitis C
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Oct 2008
Price :
$35
*
At a glance
- Drugs Nitazoxanide (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Romark Laboratories
- 01 Sep 2008 Secondary endpoint 'Viral load' has been met.
- 01 Sep 2008 Secondary endpoint 'Sustained virological response rate' has been met.
- 01 Sep 2008 Primary endpoint 'Virological response rate' has been met.